Wellington Management
Institutional crossover manager, dominant in biotech rounds.
Crossover & Growth Co-InvestorsFirmGlobal
Target market
Late-stage growth and biotech companies approaching IPO
Geography
Global
Overview
Wellington Management, the Boston institutional manager founded in 1928 with over $1 trillion in client assets, has run a dedicated private-investment platform since 2014 spanning late-stage growth and biotech. It is one of the most frequent names in biotech crossover rounds — the syndicate slot that signals a company is being positioned for the public markets.
Key facts
- Founded 1928; over $1T in client assets
- Built a dedicated private-investment platform starting in 2014
- Among the most active institutions in biotech crossover rounds